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Abstract 
Purpose: To describe the three-dimensional magnetic reso- 
nance angiography (3D MRA) imaging appearance of the 
pulmonary arteries following administration f a superpara- 
magnetic iron oxide blood pool agent o human volunteers, 
and to demonstrate in an animal model (pigs) how this 
technique can be used to detect pulmonary parenchymal 
hemorrhage. 
Methods: Two volunteers were examined following the intra- 
venous administration fa superparamagnetic iron oxide blood 
pool agent (NC100150 Injection, Nycomed Amersham Imag- 
ing, Wayne, PA, USA). Tl-weighted 3D gradient recalled echo 
(GRE) image sets (TR/TE 5.1/1.4 msec, flip angle 30 ~ were 
acquired breathheld over 24 sec. To assess the detectability of 
pulmonary bleeding with intravascular MR contrast, pulmonary 
parenchymal injuries were created in two animals under general 
anesthesia, nd fast Tl-weighted 3D GRE image sets collected 
before and after the injury. 
Results: Administration ofthe intravascular contrast in the two 
volunteers resulted in selective nhancement of the pulmonary 
vasculature permitting complete visualization and excellent de- 
lineation of central, segmental, and subsegmental arteries. Fol- 
lowing iatrogenic injury in the two animals, pulmonary 
hemorrhage was readily detected on the 3D image sets. 
Conclusion: The data presented illustrate that ultrafast 3D GRE 
MR imaging in conjunction with an intravenously administered 
intravascutar blood pool agent can be used to perform high- 
quality pulmonary MRA as well as to detect pulmonary hem- 
orrhage. 
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The imaging performance of fast three-dimensional MR 
angiography (3D MRA) with regard to the pulmonary arter- 
ies may be enhanced by the use of intravascular MR contrast 
agents [1]. Since the long intravascular half-life of intravas- 
cular MR contrast agents no longer limits data collection, the 
pulmonary vasculature can be imaged repeatedly [ 1 ]. More- 
over, any disruption of pulmonary arterial vascular integrity 
should result in extravasation a d accumulation f the intra- 
vascular agent within the pulmonary parenchyma, permitting 
easy detection and localization of hemorrhagic sites. 
The availability of high-performance gradient systems 
has shortened imaging times sufficiently to permit collection 
of a complex 3D gradient recalled echo (GRE) data set 
within the confines of a convenient breathhold [2]. In con- 
junction with the well-timed administration of an intrave- 
nous bolus of extracellular, Tl-shortening paramagnetic 
contrast agents, the entire pulmonary arterial vasculature can 
be imaged with sufficient spatial resolution to resolve even 
sixth-generation vessels [3]. 
Pulmonary hemorrhage can be either localized or diffuse 
[4]. Diffuse pulmonary hemorrhage is rare. Caused by an 
immune or coagulation disorder, it can lead to hemoptysis 
and iron deficiency anemia [5]. Localized pulmonary hem- 
orrhage, on the other hand, is considerably more common 
and usually secondary to chronic bronchitis, bronchiectasis, 
tumors, or localized infections. Delivery of potentially life- 
saving surgical, endobronchial, or endovascular therapy is 
predicated upon the quick and accurate localization of the 
bleeding site. The value of plain chest radiography, high- 
resolution CT, and fiberoptic bronchoscopy in this regard is 
firmly established. Despite the use of these modalities, lo- 
calization of bleeding sites can remain difficult or even 
impossible [6, 7]. 
This study addresses the value of 3D MR imaging fol- 
lowing the intravenous administration of an intravascular 
superparamagnetic iron oxide blood pool agent. The under- 
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lying imaging technique for visualization of the pulmonary 
vasculature using maximum intensity projections (MIPs) is 
illustrated. In addition, the use of this technique for detecting 
pulmonary parenchymal bleeding is demonstrated in pigs. 
Materials and Methods 
Intravascular Contrast Agent 
NC100150 Injection (Nycomed Amersham Imaging, Wayne, PA, 
USA) is a new MR blood pool contrast agent. It is a colloidal 
preparation of ultrasmall superparamagnetic iron oxide crystals 
with an oxidized starch coating. One milliliter of NC100150 Injec- 
tion contains 30 mg of iron (Fe). The total particle diameter (iron 
oxide core with coating) is less than 25 nm. Superparamagnetic iron 
oxide contrast agents are endocytosed and metabolized by cells of 
the reticuloendothelial system (RES), primarily by the Kupffer cells 
in the liver. The iron is incorporated into the normal metabolic iron 
pool in the same way as iron is absorbed from the diet. This agent 
has been shown to be safe in phase I trials on human volunteers, 
when administered intravenously asa bolus in doses up to 4 mg/kg 
body weight [8]. The vascular half-life in humans is dose-depen- 
dent and ranges from 3 to 4 hr [8]. NC100150 causes considerable 
shortening of both T1 and T2 relaxation times. On heavily T1- 
weighted fast 3D GRE acquisitions, characterized by short repeti- 
tion (TR) and echo (TE) times, the Tl-shortening effects 
predominate [8]. 
MR Imaging 
All MR imaging was performed on a 1.5-Tesla (T) MR system 
(Signa EchoSpeed; GE Medical Systems, Milwaukee, WI, USA) 
equipped with an ultrafast three-axis gradient system characterized 
by an amplitude of 22 mT/m and a slew rate of 140 mT/m/msec. An 
anteroposterior phased-array surface coil (torso array coil) was used 
for signal reception. Patients were imaged in the supine position 
with their arms above their head to prevent aliasing. 3D MRA data 
were acquired using a 3D Fourier transform GRE sequence with 
spoiling gradients in the coronal plane [2]. TR and TE were 5.1 and 
1.4 msec, respectively. The flip angle was 30 ~ The sampling 
bandwidth was + 62.5 kHz. A 40 • 40 cm FOV coupled with a 
256 • 192 matrix rendered an in-plane resolution of 1.5 mm• 2.1 
mm. Partial (0.6) k-space sampling in the phase-encoding direction 
permitted the breathheld acquisition of 48 contiguous coronal sec- 
tions in 24 sec. A section thickness of 2.0 mm covered an antero- 
posterior volume of 96 mm. 
The imaging data were postprocessed into MIPs as well as 2-mm- 
thick 3D multiplanar reformations in the axial and coronal planes. 
Human Imaging 
Two healthy male volunteers (22 and 24 years old) underwent MR 
imaging of the chest following the intravenous administration of
NC100150. The contrast material was administered by hand at a 
rate of approximately 3 ml/sec via a 20 gauge needle placed in the 
antecubital vein. The first subject received a dose of 3 mg Fe/kg 
body weight (6.5 ml) and the second subject a dose of 4 mg Fe/kg 
body weight (10.6 ml). The study had been approved by the 
Institutional Review Board of our hospital, and written informed 
consent was obtained from both subjects prior to beginning the 
study. Various safety parameters including blood pressure, heart 
rate, and body temperature were monitored continuously over the 
first 30 rain following injection and subsequently at set intervals. A
12-lead electrocardiogram was acquired at 1, 2, 24, 48, and 72 hr 
following injection. Fluids for laboratory parameters ( erum chem- 
istry, hematology, and urinalysis) were collected at 10 min and 2, 
24, 48, and 72 hr following injection. All data were compared with 
baseline values determined 24 hr and 30 min prior to injection. 
Qualitative assessment of the MR images was based on visual 
interpretation f image quality. Signal intensity measurements were 
performed in a region of interest (ROI) placed within the pulmo- 
nary outflow tract, both central arteries, and all five lobar arteries, 
as well as in one segmental nd one subsegmental artery of each 
lobe. Based on these 18 different measurements per 3D data set, the 
contrast-to-noise ratio (CNR) was calculated by dividing the abso- 
lute difference between the intravascular signal intensities and 
those determined in adjacent lung parenchyma by the standard 
deviation of the background image intensity [9]. 
Animal Experiments 
Two female pigs weighing 35 and 41 kg were studied. The exper- 
iments were approved by the local animal use committee and 
conducted in accordance with all state regulations governing animal 
experiments. All procedures were performed under general anes- 
thesia induced intravenously with ketamine-HC1 50 mg/10 kg 
body weight (Ketasol, Dr E. Gr~iub, Berne, Switzerland) and aza- 
perone 10 rag/10 kg body weight (Stresnil, Veterinaraia, Zurich, 
Switzerland). Both animals were intubated and fully relaxed with 
pancuronium bromide 84 mg/2 hr (Pavulon, Organon, Teknika, 
Pfaeffikon, Switzerland). The anesthetic effect was maintained 
throughout the experiments by ventilating the animals with halo- 
thane 1.5% (Synmedic, Zurich, Switzerland). 
Following the intravenous bolus administration f NC I00150 in 
a dose of 4.0 mg Fe/kg body weight, the animals were imaged in the 
supine position. Based on 2D GRE localizing images, a 3D GRE 
data set was acquired of the pulmonary arteries in the coronal plane, 
using the parameters outlined above. Subsequently, a parenchymal 
lesion was created percutaneously with a 14 gauge needle in the 
lower lobe of the left lung. The needle path was monitored on fast 
2D GRE images. Subsequent 3D GRE data sets were collected at 
4-rain intervals for 20 min. 
Following completion of the experiment, he animals were 
killed by intravenous injection of potassium chloride. The lung was 
inspected for the presence of blood and confirmation of the local- 
ization of the parenchymal hemorrhage. 
Analysis of the imaging data acquired uring the animal exper- 
iments was based on individual sections, MIPs, and 2-mm-thick 
multiplanar reformations in the axial and sagittal planes. 
Results 
Human Volunteers 
The intravenous administration of NC100150 was well tol- 
erated by both subjects. There were no serious adverse 
events. No clinically significant changes were recorded. Lab- 
oratory analysis revealed an expected increase in serum iron. 
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Fig. 1. Maximum intensity projection (MIP) reconstructions 
of 3D magnetic resonance angiography (MRA) data sets col- 
lected after the intravenous administration f NC100150 in 
normal volunteers. With both dosages (A, 3 mg Fe/kg body 
weight; B 4 mg Fe/kg body weight) the pulmonary arteries are 
visualized to the subsegmental evel. Note the presence of 
overlapping veins. 
Table 1. Contrast-to-noise ratios (CNR) of the pulmonary outflow tract, 
main stem, Lobar, and segmental arteries 
3 mg Fe/kg 4 mg Fe/kg 
body weight body weight 
Outflow tract 32 32 
Main stem artery 26 _+ 2 22 _+ 2 
Lobar arteries 22 _+ 5 28 _+ 2 
Segmental rteries 19 _+ 8 22 _+ 5 
Subsegmental arteries 11 _+ 3 15 _+ 3 
High-quality MR angiograms were obtained with both 
doses (Fig. 1). The pulmonary arteries were depicted to the 
level of sub-subsegmental arteries. Pulmonary veins en- 
hanced to the same degree as pulmonary arteries. Venous 
overlap obscured assessment of the arterial morphology on 
MIP images. Arteriovenous differentiation was easily ac- 
complished, however, based on the coronal images, axial, 
and sagittal reformations. 
The qualitative assessment is mirrored by the quantitative 
analysis (Table t). CNR values were dependent on dose as 
well as on vessel size and location. They ranged from 26 to 
28 in the outflow tracts, from 19 to 22 in the segmental 
pulmonary arteries, and from 1l to 15 in subsegmental 
pulmonary arteries. Mean CNR averaged over all 18 mea- 
surement locations was 19 _+ 8 for the 3 mg Fe/kg body 
weight dose and 23 + 7 for the 4 mg Fe/kg body weight 
dose. A paired Student's t-test revealed the differences be- 
tween the two measurement sets to be statistically significant 
(p < 0.05). 
Animal Experiments 
The animals remained hemodynamically stable throughout 
the experiments. 3D data sets collected following the intra- 
venous administration of NC 100150 depicted the pulmonary 
arteries as homogeneously bright structures to their subseg- 
mental evel. The bleeding sites within the left lower lobes 
were identified as enlarging areas of bright signal on the 3D 
data sets. Over time the contrast spread within the pulmonary 
parenchyma became clearly visible (Fig. 2). The relationship 
between the bright pulmonary vasculature and the bleeding 
site was well delineated. Reflecting the percutaneous nature 
of the injury, contrast accumulation was observed in the 
pleural space over time. In both animals, autopsy findings 
confirmed the location of the pulmonary lacerations in the 
lower lobe of the left lung. 
Discussion 
Administration of NCI00150 Injection caused no adverse 
effects in the two human subjects. In conjunction with fast 
Tl-weighted 3D GRE sequences, the intravascular agent 
provided complete visualization of the pulmonary arterial 
tree to a subsegmental level. Beyond considerably widening 
the imaging window for repeated and possibly even high- 
resolution 3D MRA of the pulmonary arteries, the agent 
appears well suited for the quick detection and accurate 
localization of pulmonary hemorrhage sites. 
Fast data cquisition strategies, based upon the availabil- 
ity of high-performance gradient systems, have laid the 
foundation for breathheld pulmonary MR imaging. T1- 
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Fig. 2. Coronal source images of 3D gradient recalled echo 
(GRE) data set following transcutaneous laceration of the 
pulmonary parenchyma of the left lower lobe in a pig. A 3D MRA 
displays the pulmonary vasculature to good advantage before the 
injury. B Following the injury there is progressive accumulation of 
the blood pool agent within the injured pulmonary parenchyma 
(arrowheads) as well as in the pleural space (arrow). C Coronal 
source image of 3D GRE data set based on the subtraction of the 
first data set following the administration of the blood pool agent 
from the second, third, and fourth data sets. Contrast 
accumulation is evident in the pulmonary parenchyma 
(arrowheads) as well as in the pleural space (arrow). Residual 
unsubtracted signal in the mediastinum reflects some motion of 
the animal between the first and subsequent acquisitions. 
weighted 3D GRE data sets with spatial resolution sufficient 
to delineate ven small structures uch as subsegmental 
pulmonary arteries can be acquired in under 20 sec [3]. 
Further improvements in gradient echnology promise to 
reduce the underlying repetition and echo times even further 
in the near future, thereby further shortening the required 
breathhold intervals [10]. 
For 3D MRA, fast 3D GRE acquisitions are timed to coin- 
cide with the intravascular phase of intravenously administered 
Tl-shortening extracellular paramagnetic contrast agents [11 ]. 
Hence, the technique provides homogeneous intravascular sig- 
nal independent of flow effects and related artifacts. Recent 
years have seen the rapid implementation of contrast-enhanced 
3D MRA for the assessment of virtually all vascular territories. 
Thus 3D MRA has been shown to be accurate in the assessment 
of the thoracic and abdominal aorta, the renal and mesenteric 
arteries, as well as the pelvic arterial system [12-15]. Similarly, 
the pulmonary arterial tree can be depicted to good advantage 
[2]. Recently Meaney et al. [16] reported contrast-enhanced 3D 
MRA to be highly accurate in the diagnosis of pulmonary 
embolism. 
To date gadolinium chelates have been used as contrast 
media for 3D MRA. The agents are limited by their extracel- 
lular nature, resulting in a short intravascular half-life due to 
rapid redistribution i to the extracellular spaces. Background 
noise induced by the extracellular redistribution anddosing 
limitations virtually prohibit repeated imageacquisitions of the 
same region in the case of technical failure or its extension to a 
second vascular territory. Breathheld contrast-enhanced 3D pul- 
monary MR imaging using gadolinium has been associated 
with a high sensitivity and specificity for the diagnosis of 
pulmonary embolism [15]. However, most pa ients with sus- 
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pected pulmonary embolism are severely dyspneic and do not 
tolerate breathheld data acquisition of large vascular territories. 
Intravascular contrast agents, by providing a long imaging 
window, promise to overcome these limitations [1]. 
NC 100150 is a colloidal presentation of coated ultrasmall 
superparamagnetic iron oxide particles, capable of inducing 
vast reductions in both T1 and T2 relaxation times (internal 
study reports, Nycomed Amersham Imaging). Employed in 
combination with an ultrafast 3D GRE acquisition charac- 
terized by short repetition and echo times, the Tl-shortening 
effects predominate, rendering the intravascular signal ex- 
quisitely bright. CNR levels within the subsegmental pulmo- 
nary arteries exceeding a value of 10 illustrate this 
phenomenon to good advantage. Although the CNR values 
were somewhat dose-dependent, favoring the higher 4 mg 
Fe/kg body weight dose, the pulmonary vasculature was 
sufficiently well delineated even with a dose of 3 mg Fe/kg 
body weight. In view of the slightly better results, the 4 
mg/kg dose was used for the animal experiments. 
High-quality arterial-phase images can be obtained with 
intravascular contrast agents by imaging dynamically during 
the arterial phase of the injection, as is currently practiced 
with extracellular gadolinium contrast agents. In addition, 
intravascular agents permit continued imaging in the equi- 
librium "intravascular" phase. This allows for repetitive im- 
aging of focused regions and may thus prove particularly 
helpful in the diagnostic investigation of patients with sus- 
pected pulmonary emboli. The image quality achieved in this 
limited study of two volunteers illustrates excellent depiction 
of the entire pulmonary arterial tree. 
Furthermore, the intravascular nature of the agent results in 
extravasation f contrast only in areas of compromised vascular 
integrity: areas of active bleeding are thus readily detected and 
accurately located. This rather simplistic observation promises 
to influence considerably the list of potential indications for 
NC100150 Injection, as well as any other intravascular contrast 
agent. Although very preliminary and somewhat crude, the 
animal experiments described here do document the feasibility 
of intravascular MR contrast agents in conjunction with fast 3D 
GRE acquisitions to locate the origin of pulmonary parenchy- 
mal hemorrhage. The long intravascular half-fife of the agent 
permits repetitive imaging over a longer time frame during 
which the agent has accumulated in the extravascular space, 
thereby enhancing conspicuity. In this respect, the proposed 
technique mimics radionuclide studies. At the same time, the 
high-resolution 3D data sets provide a detailed epiction of the 
surrounding vascular and parenchymal morphology similar to 
conventional ngiography. 
Bleeding from the lung is most frequently caused by a 
local injury to the vascular bed induced by processes such as 
chronic bronchitis, bronchiectasis, tumors, or localized in- 
fections. The diagnostic investigation of pulmonary bleeding 
remains controversial [6, 7]. The combined use of ffberoptic 
bronchoscopy and CT has to date yielded the best results in 
the investigation of patients with hemoptysis [6]. Despite 
best efforts, pulmonary bleeding sites often remain uniden- 
tiffed, even in patients with moderate to severe hemoptysis 
[6, 7]. Fast 3D GRE imaging in the presence of intravascular 
blood pool agents promises to solve this diagnostic dilemma. 
In addition, the technique may prove useful in the charac- 
terization of diffuse pulmonary diseases, based upon their 
effect on the integrity of the vascular bed. Thus it is con- 
ceivable that this technique may permit an earlier or more 
specific diagnosis of angiocentric disease processes, uch as 
invasive aspergillosis, known to cause micro-infarctions 
with localized pulmonary hemorrhage. 
In summary, the data presented here illustrate that ultra- 
fast 3D GRE MR imaging in conjunction with an intrave- 
nously administered intravascular blood pool agent can be 
used to perform high-quality pulmonary MRA as well as to 
detect pulmonary hemorrhage. 
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